Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Butorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 17/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butorphanol SCHEMBL11529206 | 1.00 | OPRK1 (0.98) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL29359664 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL3749 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL19427408 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL27701479 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL10031253 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL16311889 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL28094979 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL20904174 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL1613498 | 0.99 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916215-A | Transdermal microdosing delivery of hallucinogen derivatives | 长矛治疗股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112004520-A | Modified release drug powder compositions comprising a gastric retentive raft forming system with triggered pulsed drug release | 特瑞斯制药公司 | 2020-11-27 | — | — | CN | disclosed |
| US-10624887-B2 | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol | RELMADA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20160235740-A1 | Compositions of (-)-17-(Cyclobutylmethyl)Morphinan-3,14,-Diol | RELMADA THERAPEUTICS, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9364430-B2 | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol | RELMADA THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2632441-A2 | COMPOSITIONS OF (-)-17-(CYCLOBUTYLMETHYL) MORPHINAN-3, 14-DIOL | Babul, Najib (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058695-A2 | COMPOSITIONS OF (-)-17-(CYCLOBUTYLMETHYL) MORPHINAN-3, 14-DIOL | BABUL NAJIB (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1829549-A1 | AMORPHOUS COMPOSITION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-4139534-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096924-A1 | Amorphous Composition | CACNA1B, CACNA1I, TRPV1 | OPRK1 278/4885OPRM1 279/4885OPRD1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.